ICC trials -- enrollment problems. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


ICC trials -- enrollment problems. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

AIDS Treat News. 1995 Apr 7;(no 220):2-3. Unique Identifier : AIDSLINE AIDS/95700339

Abstract: Some controversy has arisen over enrollment procedures for the Inter-Company Collaboration for AIDS Drug Development (ICC) trials. Potential participants must submit blood work that has been done within the preceding thirty days that shows probable eligibility (CD4 counts between 200 and 500 with no AZT therapy experience). It is commented that this pre-screening requirement delays enrollment considerably in a trial that has already experienced major delays. The pre-enrollment requirements are seen as an example of cost shifting from those who could afford it to those least able to pay.
Keywords: Chemistry, Clinical Clinical Trials *Eligibility Determination Health Care Costs Human Lymphocyte Subsets NEWSLETTER ARTICLE

KWDchemistry,clinicalclinicaltrialsKWDeligibilitydeterminationhealthcarecostshumanlymphocytesubsetsnewsletterarticle
951130
M95B0916

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .